GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score–matched population-based cohort study
Main finding · Incident HCCResult — go to the resultAdjusted hazard ratio 0.64 95% CI 0.42–0.98Authors' conclusion
GLP-1RA use was associated with significantly reduced risks of HCC and death in patients with MASLD and T2DM, supporting its potential for HCC chemoprevention.
Study context
- Population
- Adults aged 18–90 years with MASLD and T2D, TriNetX global network, 2005–2025matched cohort
- Participants
- 152,329 vs 152,329
- Exposure
- GLP-1 RA use vs non-use
- GLP-1RAn = 152,329
- No GLP-1RAn = 152,329reference
- Outcome
- Incident hepatocellular carcinoma (HCC)
Methodological detailsmultinational, propensity-score matched, population-based
- Multinational
- Propensity-score matched
- Population-based
Main finding
As reported in the abstract
Adjusted hazard ratio
0.64
95% CI 0.42–0.98
GLP-1RAvs No GLP-1RA
aHR 0.64 (95% CI 0.42–0.98)
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| All-cause mortality | 0.37 (0.36–0.38) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Subgroup, sensitivity and control analyses
- Subgroup, sensitivity, and control analyses supported the robustness of findings
Original publication
GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score–matched population-based cohort study. Diabetes Res Clin Pract. Published 11 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →